In another study, fenofibrate, a PPAR-α agonist, was found to alleviate resistance to gefitinib in NSCLC cell lines by modulating the PPAR-α/AMPK/AKT/FoxO1 signaling pathway and demonstrated that the increased antiproliferative effect of fenofibrate was abolished when PPAR-α was silenced [48]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.